Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of .
Arch BiopartnersDecember 10, 2020 GMT
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System (VASDHS) has started recruiting patients for the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.
Share:
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) Arch Biopartners Inc. ( Arch or the Company ) (TSXV:ARCH, OTCQB:ACHFF), announced today that the Veterans Affairs San Diego Healthcare System (VASDHS) has started recruiting patients for the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19. Acute lung injury and acute kidney injury are among the most serious consequences of COVID-19, and novel medications focused on preventing these organ failures have the potential to be life-saving. We are excited to be part of this research, and to give our Veterans the opportunity to participate in this trial, said Dr. Mark Hepokoski, M.D. a pulmonary and critical care physician at the VASDHS and site principal investigator for the LSALT Phase II trial.